Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT study
HIV Clinical Trials, Volume 11, No. 3, Year 2010
Notification
URL copied to clipboard!
Description
Background: The MERIT study evaluated maraviroc versus efavirenz, both with zidovudine/lamivudine, in treatment-naïve patients with CCR5-tropic (R5) HIV-1. Post hoc analyses previously assessed week 48 outcomes in patients rescreened with R5 virus by a more sensitive tropism assay. Methods: Week 96 efficacy (post hoc, n = 614) and safety (n = 721) were assessed. Results: Proportions of subjects <50 copies/mL (58.8% maraviroc, 62.7% efavirenz) and time to loss of virologic response (TLOVR) responders (<50 copies/mL: 60.5% vs 60.7%) were similar. Maraviroc recipients had greater CD4 increases (+ 212 vs + 171 cells/mm3) and fewer adverse event discontinuations (6.1% vs 15.5%), malignancies, and category C events. Conclusion: Week 96 data confirm week 48 observations in MERIT. © 2010 Thomas Land Publishers, Inc.
Authors & Co-Authors
Sierra-Madero, Juan Gerardo
Mexico, Tlalpan
Instituto Nacional de la Nutrición Salvador Zubiran
Di Perri, Giovanni
Italy, Turin
Ospedale Amedeo Di Savoia
Wood, Robin Y.
South Africa, Cape Town
University of Cape Town
Saag, Michael S.
United States, Birmingham
The University of Alabama at Birmingham
Frank, Ian D.
United States, Philadelphia
University of Pennsylvania
Craig, Charles
United Kingdom, Tadworth
Pfizer Limited, uk
Burnside, Robert
United States, New York
Pfizer Inc.
McCracken, Jennifer
United States, New York
Pfizer Inc.
Pontani, Dennis
United States, New York
Pfizer Inc.
Goodrich, James M.
United Kingdom, Brentford
Viiv Healthcare
Heera, Jayvant R.
United States, New York
Pfizer Inc.
Mayer, Howard B.
United States, New York
Pfizer Inc.
Statistics
Citations: 69
Authors: 12
Affiliations: 8
Identifiers
Doi:
10.1310/hct1103-125
ISSN:
15284336
Research Areas
Infectious Diseases